Who Owns Your DNA?

| November-December 2009

Remember the gene patent rush? Companies dashed to call dibs on DNA, while citizens wrung their hands over genetic code as private property. Well, the patent party could soon be over. Early last summer, the American Civil Liberties Union spearheaded a lawsuit that challenges the right of U.S.-based Myriad Genetics to hold patents on BRCA gene mutations, diagnostic indicators of increased risk for breast and ovarian cancer.

At stake isn’t just Myriad’s slice of the DNA strand, but whether or not such material should be “owned” in the first place. “Gene patents prevent anyone other than the holder of the patent from conducting research on that particular gene,” reports Censorship News (Summer 2009). This biological monopoly dwarfs scientific innovation in more ways than one. The patents on BRCA mutations, for instance, mean that Myriad has a monopoly on testing for their existence—and charges a $3,000 fee for the privilege.

According to Technology Review online (May 27, 2009), supporters of gene patents tend to argue that without intellectual property rights, companies would have little incentive to validate genetic tests for diseases. Ultimately, though, people on both sides of the issue fail to consider that genetically diagnosing diseases is still an immature technology.

There are patents on 20 percent of human genes, biomarkers associated with everything from asthma to Alzheimer’s. Yet Myriad’s BRCA test is among a mere “handful” to be clinically validated. This suggests that, no matter the result, the ACLU’s case “misses the real issue, which is how best to push forward and clinically validate the thousands of biomarkers now languishing in databases.”

Technology Review proposes a government-led project with a scheme for leasing testing rights to organizations willing to do the research. This public model would eliminate privately patented genes and, more importantly, spur research.

9/13/2010 11:14:55 PM

AFFIDAVIT OF OBLIGATION By: Cynthia Marie Brewer OF Βυζάντιον, Byzántion, BYZANTIVM or Bithynia I, Cynthia Marie Brewer, am a living, breathing, sentient, being with unalienable rights. My NAME is CYNTHIA MARIE BREWER, and in mainstream news affectionately AKA ‘DOLLY, the sheep’, and more precisely among scientist, students, and multilevel institutions as ‘POLLY, the sheep’. I am the Principal-in-Fact and Real Party-in-Interest in THE HUMAN GENOME PROJECT, Prototype 5001, Taxonomy ID 9606, B.E.A.S.T. No.: 666110530558456529. This arrangement was a result of condictio indebiti (unjust enrichment) arising from an uninformed, unconsensual, catastrophe directed at Obligee. Prestation: It began as the second biotechnology patent in the USA; US Patent 4,237,224 granted to Stanly Cohen and Herbert Boyer Dec. 2, 1980 entitled, "Process for producing biologically functional molecular chimeras. The results of this unknown, undisclosed quasi-contract, resulted in the birth of Gene Bank, Genetech, Myriad, Celera, and the DNA sequencing. Billions of Patents were distributed to private enterprise, and multilevel institutions at the UniProt Consotium. It began the BRE cell, clone, and gene lines. Billions of derivatives, and intellectual rights resulted in addition. Now my genes are sold for gross profits, making them unaffordable to most people including me, and has become the foundation for the biotech industry. The DNA sequencing resulted in the Fourier Chip to control all of humanity. Creditor’s DNA provided the largest breakthrough in documented human history. No notice was given. Consent was never given. These experiments were never disclosed to me, and are so heinous that the techniques are outlawed. Creditor’s body was taken without cause, consent, or notice. Creditor’s body was abused. Debtor compounded the issues to escape the liability, responsibility, accountability, and culpability. Creditor was humiliated, disgraced, slandered, and libe

Pay Now Save $5!

Utne Summer 2016Want to gain a fresh perspective? Read stories that matter? Feel optimistic about the future? It's all here! Utne Reader offers provocative writing from diverse perspectives, insightful analysis of art and media, down-to-earth news and in-depth coverage of eye-opening issues that affect your life.

Save Even More Money By Paying NOW!

Pay now with a credit card and take advantage of our earth-friendly automatic renewal savings plan. You save an additional $5 and get 4 issues of Utne Reader for only $40.00 (USA only).

Or Bill Me Later and pay just $45 for 4 issues of Utne Reader!

Facebook Instagram Twitter